Merck to pay landmark $688m in no-wrongdoing settlement of ENHANCE suits
This article was originally published in Scrip
Executive Summary
Merck admitted no wrongdoing in its $688 million settlement with shareholders who sued the company and Schering-Plough for allegedly withholding crucial data from the ENHANCE clinical trial for the cholesterol-lowering combination drug Vytorin.